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Objective: To investigate the clinical features of dementia with Lewy bodies (DLB) in a Chinese population.
Methods: Computer-based online searches through China Biology Medicine disc and China National Knowledge
Infrastructure were performed to collect case reports of DLB published between 1980 and 2012. Clinical
characteristics were analyzed.
Results: A total of 18 studies comprising 35 patients (26 males and 9 females) were included. The mean age at
onset was 67.2 ± 9.8 years. Onset was characterized by memory impairment and accounted for 58.8% of all cases,
followed by parkinsonism (11.8%), visual hallucinations (8.8%), and compulsive personality disorder (2.9%). The other
patients (17.6%) presented two of the three core features of DLB at onset. With disease progression, parkinsonism
was reported in 100% of cases, followed by visual hallucinations (97.1%), psychiatric symptoms (85.7%), severe
neuroleptic sensitivity (81.8%), fluctuating cognition (68.6%), repeated falls (40.0%), sleep disorders (22.9%), and
transient loss of consciousness (17.1%). 26 patients who were subjected to Mini-Mental State Examination
scored ≤ 24. 10 patients presented relative preservation of hippocampus and medial temporal lobe structures
on CT/MRI scan. Occipital hypometabolism occurred in 2 of 3 patients who underwent SPECT/PET perfusion
scan. 12 patients showed an increasing of slow frequency activity on EEG, prominently in frontal and temporal
lobes.
Conclusions: DLB often strikes elderly individuals. Its clinical core features are dementia, fluctuating cognition,
recurrent visual hallucinations and spontaneous features of parkinsonism. Neuropsychological, neuroimaging
and EEG examinations may improve the diagnostic accuracy and discriminate DLB from other dementias.
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diseaseIntroduction
Dementia with lewy bodies (DLB) is the second most
prevalent cause of degenerative dementia after Alzheimer
disease (AD) in older people, accounting for 10% of all
cases [1]. Its clinical features include dementia, fluctuat-
ing cognition, visual hallucinations and parkinsonism
[2]. The main neuropathological findings are Lewy bodies
(LBs), senile plaques (SP) and less or no neurofibrillary
tangles (NFT) [3]. To date, DLB is more common than
previously thought. However, less systematically studies of
DLB are published in China. The present study aimed to* Correspondence: zhenfuw@sina.com
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reproduction in any medium, provided the orreview clinical features of DLB through a thorough ana-
lysis of Chinese DLB reports published from 1980 to 2012.Data and methods
Subjects
Data inclusion and exclusion criteria
Pre-indexing did not reveal any systematic evaluations,
prospective cohort studies, retrospective cohort studies,
bioecological studies, or non-consecutive cohort studies
of DLB in China. Case or individual reports published
between January 1, 1980 and November 1, 2012 were in-
cluded, but reviews and experimental studies of DLB
were excluded.. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.







Lu H et al. [4] 1 1/0 66/
Wang Y et al. [5] 1 0/1 /77
Gai QW et al. [6] 2 2/0 69,67/
Yang GE et al. [7] 1 1/0 50/
Chen L et al. [8] 8 6/2 63 ~ 72
Zhang XQ et al. [9] 1 0/1 /63
Wu XP [10] 4 2/2 68,66/58, unknown
Yang WM [11] 3 3/0 56,56,75/
Li YM et al. [12] 1 1/0 70/
Wang EZ [13] 1 0/1 /40
Xian HT [14] 2 2/0 68,75/
W R et al. [15] 1 0/1 /74
Li JL et al. [16] 1 1/0 72/
Liu XS et al. [17] 4 4/0 71,74,76,77/
Wang XH et al. [18] 1 1/0 53/
Fu YH et al. [19] 1 0/1 /81
Yang L et al. [20] 1 1/0 70/
Lu WF et al. [21] 1 1/0 76/
Han et al. Translational Neurodegeneration 2014, 3:1 Page 2 of 5
http://www.translationalneurodegeneration.com/content/3/1/1Subject inclusion criteria
The current criteria for DLB diagnosis in China have
been defined by the DLB Consortium in 2005. Dementia
is the essential condition for a diagnosis of possible or
probable DLB. The core features of DLB include fluctu-
ating cognition with pronounced variations in attention
and alertness, recurrent visual hallucinations that are
typically well formed and detailed, and spontaneous fea-
tures of parkinsonism. Two or more core features is suf-
ficient for a diagnosis of probable DLB, one for possible
DLB. The suggestive features of DLB include rapid eye
movement sleep behavior disorder (RBD), severe neuro-
leptic sensitivity, and low dopamine transporter uptake
in basal ganglia demonstrated by SPECT or PET im-
aging. If one or more of suggestive features is present in
the presence of one or more core features, a diagnosis of
probable DLB can be made. In the absence of any core
features, one or more of suggestive features is sufficient
for possible DLB. Probable DLB should not be diagnosed
on the basis of suggestive features alone [2].
Retrieval methods
“Dementia with lewy bodies, DLB, lewy body dementia,
diffuse lewy body disease, DLBD, lewy body disease”
were used as key words to search the China Biology
Medicine disc and China National Knowledge Infra-
structure for related articles published between 1980
and 2012.
Data extraction
Age at onset, initial symptoms, clinical manifestations, la-
boratory examinations were extracted and recorded for
each patient. The data were analyzed by SPSS version 13.0.
Results
A total of 81 articles related to DLB were collected. 63
articles were excluded for duplication, non-clinical re-
search or lacking of essential clinical materials. A total
of 18 studies comprising 35 DLB patients were included
(26 males and 9 females), with a mean onset age of 67.2 ±
9.8 years (range 40–81 years). General characteristics of
the included articles are listed in Table 1. There were no
significant differences between male and female patients
in terms of age of onset (male: 67.8 ± 8.0 years, female:
65.5 ± 15.2 years, P > 0.05).
Clinical manifestations
Of the 34 patients who had detailed initial clinical mani-
festation records (1 patient’s initial clinical manifestation
was not mentioned), 20 patients (58.8%) showed cogni-
tive decline, 4 (11.8%) showed parkinsonism, 3 (8.8%)
showed visual hallucinations, 3 (8.8%) presented cognitive
decline with parkinsonism, 2 (5.9%) presented cognitivedecline with visual hallucinations, 1 (2.9%) presented vis-
ual hallucinations with parkinsonism.
During the progression of the disease, 24 patients
(68.6%) displayed fluctuating cognition that appeared
within one day to several weeks. 34 patients (97.1%) suf-
fered from recurrent visual hallucinations that were well
formed and detailed. 35 patients (100%) manifested the
symptoms of parkinsonism, including rigidity, bradyki-
nesia, postural instability and gait difficulty (8 patients
presented rest tremor). 8 patients (22.9%) had sleep dis-
order, 4 of them exhibited RBD. 14 patients (40%) had
the experience of repeated falls because of postural in-
stability (12 patients), transient loss of consciousness
(1 patient) and paroxysmal vertigo (1 patient). 1 patient
(2.9%) presented orthostatic hypotension. 30 patients
(85.7%) had neuropsychiatric symptoms, including irrit-
ability, apathy, auditory hallucination, illusion, anxiety and
depression.
3 patients were confirmed by autopsy. The disease
courses of the 3 patients were 2.5 years, 3 years and 11
years respectively. The initial symptoms were parkinson-
ism with hallucinations, parkinsonism with cognitive de-
cline, and cognitive decline respectively. During the
progression of the disease, all the 3 patients shared the
same clinical features of parkinsoniam and cognitive de-
cline. 2 of them presented visual hallucinations. 2 pa-
tients had exacerbated symptoms after the treatment of
anti-parkinsonism drugs. 2 patients were died from mul-
tiple organ failure and 1 was from stroke. All the 3 patients
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phy dominantly in medial hippocampus, parahippocampal
gyrus, entorhinal cortex and amygdala. LBs were widely
distributed in the cortical and subcortical regions of the
brain, including substantia nigra, locus coeruleus, frontal
lobe, parietal lobe, cingulate gyrus, meynert’s nucleus, et al.
Further pathological features were not mentioned.
Laboratory examinations
A total of 26 patients were subjected to Mini-Mental
State Examination (MMSE) evaluation and mean score
was (12.2 ± 5.6). 34 patients who underwent CT/MRI ex-
aminations presented diffuse brain atrophy, 10 of them
(29.4%) showed relative preservation of medial temporal
lobe and hippocampus, and 1 patient (2.9%) showed
prominent temporal lobe atrophy. Of the 3 patients who
underwent SPECT/PET examinations, 1 patient showed
low dopamine transporter uptake in right striatum, 1
showed low fluorodeoxyglucose uptake in left frontal
lobe, bilateral posterior temporal, parietal and occipital
lobes, and the last one showed generalized low uptake.
Of the 19 patients who underwent electroencephalogram
examinations, 12 patients showed an increasing of slow
frequency activity in frontal and temporal lobes, 4 showed
mild to moderate abnormalities, and 3 showed normal re-
sults. 1 patient underwent polysomnography examination
and the result was abnormal.
Therapy
Of the 24 patients who were treated with L-dopar, 12
patients had a mild to moderate improvement in extra-
pyramidal symptoms, 11 patients had no significant im-
provement, 1 patient was subject to exacerbation. 2
patients who were treated with selegiline had a mild im-
provement. Of the 5 patients who had used artane, 2 pa-
tients had no significant improvement, and 3 patients
suffered from aggravating hallucinations and psychiatric
symptoms. 2 patients who were treated with amantadine
had no significant improvement. 1 patient was reported
to have a bad performance after taking piribedil. Of the
12 patients who had used the neuroleptic agents, 11 pa-
tients showed severe neuroleptic sensitivity (6 patients
used perphenazine, 2 patients used risperidone, 1 patient
used clozapine, 1 patient used olanzapine, 1 patient used
haloperidol), and 1 patient had a mild improvement after
using a small dose of quetiapine. 8 patients who were
treated with donepezil (5-10 mg/d) had a mild to mod-
erate improvement in dementia and neuropsychiatric
symptoms.
Discussion
DLB is a neurodegenerative disease. It is reported a
prevalence range from 0 to 5% with regard to the gen-
eral population, and the incidence of DLB is 0.1% a yearfor the general population [22]. An accumulation of pro-
teins including α-synuclein aggregates in cortical and
subcortical regions of the brain is the main neuropatho-
logical findings [23]. Its core clinical features include
fluctuating cognition with pronounced variations in at-
tention and alertness, recurrent visual hallucinations that
are typically well formed and detailed, and spontaneous
features of parkinsonism [2]. Despite its high prevalence,
few cases have been reported in China, and no related
epidemiological data has been reported too. We aim to
systematically investigate the clinical features of DLB in
a Chinese population as well as to raise the clinicians’
consciousness of the disease through this article.
In the present study, the mean age of onset was
(67.2 ± 9.8) years (range from 40 ~ 81years), which was
consistent with previous reports [24]. There were no sig-
nificant differences between males and females in age of
onset (P > 0.05). The present study confirmed that cogni-
tive decline was the most commonly reported symptoms
at disease onset, whereas visual hallucinations and par-
kinsonism were less likely to happen. Previous studies
found deficits on tests of attention, executive function,
and visuospatial ability may be especially prominent in
the early stage and memory impairment may not neces-
sarily occur [2], which was not consistent with the
present result of memory loss being much more com-
mon at disease onset. Most patients in the present study
showed bilateral symmetric parkinsonism with promin-
ent axial rigidity and less rest tremor. Half of 8 cases
who had sleep disorders presented RBD, the incidence
rate of which was lower than it was previously reported
[25]. Ferman et al. [26] have found that inclusion of RBD
as a core clinical feature improves the diagnostic accur-
acy of autopsy-confirmed DLB. When RBD was added
and clinically probable DLB reflected 2 or more of 4 fea-
tures, sensitivity improved to 88%. When dementia and
RBD were also designated as probable DLB, sensitivity
increased to 90% while specificity remained at 73%. A
high proportion of patients with neuropsychiatric symp-
toms were found in this study. Neuropsychiatric symp-
toms may complicate the clinical diagnosis of DLB [27],
patients who presented neuropsychiatric symptoms at
onset were often misdiagnosed for psychosis. In the
present study, 30 patients showed dementia occurred be-
fore parkinsoniam, and 1 case showed dementia oc-
curred after paikinsoniam within half a year. The other 4
patients presented dementia occurred 2–3 years later in
the context of confirmed paikinsonism. These 4 patients
fulfilled the clinical criterion of probable DLB. The exist-
ing 1-year rule suggests Paikinson disease dementia
(PDD) should be used to describe dementia that occurs
at least 1 year later than parkinsonism. However, Tsuboi
et al. [28] found that PDD and DLB shared few differ-
ences at autopsy, so 1 year rule may be not compatible
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the 4 patients have been reported, we couldn’t confirm
that they share the same features with Tsuboi’s cases.
29.4% of patients who underwent CT/MRI examinations
showed relative preservation of medial temporal lobe
and hippocampus, which is helpful to distinguish from
AD patients who presented marked atrophy in temporal
lobe and hippocampus [29]. 2 patient who underwent
FDG-PET scan displayed low metabolism in bilateral oc-
cipital lobes, which is consistent with the result of Feng’s
[30] and is helpful for differentiating DLB from other
types of dementia. Another patient exhibited low dopa-
mine transporter uptake in right striatum, which had an
important significance for differentiation between DLB
and AD. However, the utilization of SPECT/PET has its
own limitation on differentiating from PD [31-33]. 3 pa-
tients who were confirmed by autopsy presented diffused
LBs in cortical and subcortical regions of the brain,
which was consistent with McKeith’s study [34].
To date, the evidence base for making recommenda-
tions about the management of DLB is limited and what
follows is based upon consensus opinion of clinicians ex-
perienced in treating DLB. Supportive and symptomatic
therapies are still the main approaches. The observation
of less neuronal loss in DLB than in AD suggests that
cortical neurons in DLB are more viable than those in
AD and could be more responsive to cholinergic stimu-
lation [35,36]. Cholinesterase inhibitors (ChEIs) may be
of benefit for the fluctuating cognitive impairments with
impact on global function and activities of daily living
[37]. It is reported that ChEIs, including rivastigmine,
galantamine and donepezil, may improve patients in
measures of attention as well as reduce in psychotic
symptoms [38-41]. In the present study, a total of 8
patients who have been treated with donepezil have
varying degrees of improvement in dementia and neuro-
psychiatric symptoms, which is consistent with previous
studies. However, we have no data about rivastigmine and
galantamine in DLB therapy among our collected patients.
Molloy et al. [42] found that L-dopa is generally well
tolerated in DLB but produced a significant motor re-
sponse in only about one third of patients. Bonelli et al.
[43] found a greater than 20% improvement in UPDRS
scores in 50% of DLB patients compared to 65% of
Parkinson’s disease with dementia patients and 90% of
Parkinson’s disease patients. Goldman et al. [44] re-
ported improvement in motor symptoms in 6 of 19
DLB patients. Of the responders, only 22% of the co-
hort is able to achieve improvement in motor symp-
toms without exacerbation of psychosis. In our study,
12 patients (50%) who have taken L-dopa have a mild
to moderate improvement in extrapyramidal symp-
toms, and 1 patient (4%) has a psychosis exacerbation.
The UPDRS scores of these patients are not reported.The effectiveness of motor benefit is consistent with
previous reports. However, the risk of psychosis exacer-
bation is lower. Although the effectiveness of L-dopa for
DLB is lower than PD, it may be beneficial to the motor
symptoms in the long run [42,45]. 2 patients who are
treated with selegiline have been reported an improve-
ment in extrapyramidal symptoms, which suggest that
monoamine oxidase B (MAOB) may have applied value
in DLB therapy.
30 patients have suffered from a variety of neuro-
psychiatric symptoms. 11 patients who have taken
neuroleptic agents have presented severe neuroleptic
sensitivity. It is suggested that typical antipsychotics (in-
cluding perphenazine, haloperidol, et al.) should be
avoided [46]. Of the 5 patients who have taken atypical
antipsychotics, only 1 patient has a mild improvement
after taking quetiapine. Thus ChEIs may be the first
option [38,40]. However, if ChEIs are ineffective or if
more acute symptom control of behavior is required, it
may be difficult to avoid a cautious trial of an atypical
antipsychotic [2].
In conclusion, Chinese DLB patients usually begin
with the symptoms of cognitive impairment which is
characterized by memory loss. With disease progression,
most patients present at least 2 or 3 core clinical fea-
tures of DLB including the symptoms of parkinsonism,
visual hallucinations and fluctuating cognition. The oc-
currence of RBD may improve the diagnostic accuracy
of DLB. Patients often suffer from psychotic symptoms
which may be exacerbated by using neuroleptic agents
and some anti-parkinsonism drugs. ChEIs may be the
first option to improve the cognition and psychotic
symptoms. L-dopar may have a limited improvement in
parkinsonism symptoms. MAOB may be effective. Oc-
cipital low uptake on FDG-PET may have significance in
differentiating DLB from other dementia. Other labora-
tory examinations may improve the diagnostic accuracy.
However, there are some problems as followed. First,
few pathological findings of Chinese DLB have been re-
ported during the past 30 years, which may influence
our further understanding of the disease. Second, DLB
have overlapped symptoms with AD, PD, PDD, psychosis
and other diseases, which may confuse clinicians to
make misdiagnosis. Third, not all the patients in our
study have detailed clinical manifestations or medica-
tions, our analyses and discussions are limited. There-
fore, detailed physical and laboratory examinations,
reasonable therapies, and long time follow-up are very
important. Early and correct diagnosis and medical
treatment provide better control for clinical symptoms
in DLB, as well as improve quality of life. The present
study reviewed literature from China for the past 30
years and analyzed clinical data from 35 cases. Results
provided a primary reference for better understanding
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early diagnostic rates, however, more researches are needed
for the limitation of few cases.
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